Abstract
Recombinant human endostatin (Endostar) is an angiogentic medicine with mild toxicity and strong efficacy in systematic treatment of NSCLC. Recently, several studies proved that Endostar combined with radiotherapy could enhance NSCLC treatment efficiency according to mechanism of microenvironment normalization. However, this combination therapy has not tested in elderly population up to now. In this trial, we observed the efficacy and safety of Endostar combined with concurrent intensity modulated radiation therapy (IMRT) for inoperable elderly local advanced NSCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
